LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma
Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 MEUR has been completed. The initial agreement with Karo Pharma was announced on December 23, 2019 and approved by relevant competition authorities on February 20, 2020.
This divestment marks an important step for LEO Pharma towards strategically aligning its portfolio and increasing focus on innovation and dermatology.
The divested products include four anti-hemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology products, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®).
Maia Fredtoft Søchting
Global External Communications
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information about LEO Pharma, visit www.leo-pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate15.4.2020 07:45:16 CEST | Press release
BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.
With topline growth of 7% in 2019, margin improvements and pipeline success, LEO Pharma paves the way for an ambitious future27.2.2020 21:00:00 CET | Press release
LEO Pharma helped 92 million patients and reached revenue of DKK 10,805 million in 2019 - 2019 revenue up by 4% to DKK 10,805 million – with a strong fourth quarter demonstrating further momentum. This was driven by strong performances of Enstilar®, Kyntheum® and the prescription portfolio acquired from Bayer. - Underlying revenue grew by 7%. This excludes currency effects, divestments of non-core business to Karo Pharma and other one-time effects. - Revenue in region Europe+ grew 5% to DKK 6,840 million, due to Enstilar®, Kyntheum® and the acquired Bayer portfolio. - Sales in region International grew 12% to DKK 3,117 million, due to the acquired Bayer portfolio. - US sales declined 22% to DKK 848 million, due to generic competition and price pressure. We continue to see the US as a key growth driver in the future and are stepping up the launch preparations for tralokinumab accordingly. Established business remains the backbone with continued growth and improved profitability - Toplin
LEO Pharma Signs Agreement to Divest Emollients and Proctology Portfolio to Karo Pharma23.12.2019 12:10:00 CET | Press release
Ballerup, DENMARK, December 23, 2019 – Today, LEO Pharma announced the sale of 10 products to Karo Pharma AB for 90 MEUR. The divested portfolio isnon-core to LEO Pharma’s business, and was part of the portfolio acquired from Bayer in July 2019. “This divestment is an important step for LEO Pharma towards strategically aligning our portfolio and increasing focus on innovation and dermatology. This well-established portfolio will be better served by Karo Pharma and its team,” said Anders Kronborg, Chief Financial Officer, LEO Pharma. The product portfolio includes four anti-haemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®). Karo Pharma is a fast-growing specialty pharma company that develops and markets products to physicians, pharmacies and directly to healthcare providers. The company is listed on the Swedish stock exchange, Nasdaq Stock
LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD11.12.2019 08:05:00 CET | Press release
BALLERUP, Denmark, December 11, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced that tralokinumab – an investigational, fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and secondary endpoints in its three pivotal Phase 3 studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo. IL-13 is a key driver of the type 2 inflammation that plays a major role in AD,(1) which is the most common inflammatory skin disease in the developed world,(2) affecting up to five percent of adults across the United States, Canada, Europe and Japan.(3) AD can have a significant, negative impact on patients’ well-being, primarily due to distressing itch, sleep deprivation and social stigmatization due to visible lesions.(4) “In its moderate-to-severe form, AD can cause unbearable
LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device4.12.2019 09:03:00 CET | Press release
Ballerup, DENMARK and Cambridge, MA, USA – December 4, 2019 – LEO Pharma A/S and Portal Instruments today announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines.
Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors14.11.2019 09:04:51 CET | Press release
BALLERUP, Denmark, November 14, 2019 – LEO Pharma A/S today announced that Birgitta Stymne Göransson has been elected member of the company’s Board of Directors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom